CD133 antisense suppresses cancer cell growth and increases sensitivity to cisplatin in vitro

Blancas-Mosqueda,Marisol; Zapata-Benavides,Pablo; Zamora-Ávila,Diana; Saavedra-Alonso,Santiago; Manilla-Muñoz,Edgar; Franco-Molina,Moisés; Mondragón De La Peña,Carmen; Rodríguez-Padilla,Cristina

doi:10.3892/etm.2012.692

CD133 antisense suppresses cancer cell growth and increases sensitivity to cisplatin in vitro

Authors:
- Marisol Blancas-Mosqueda
- Pablo Zapata-Benavides
- Diana Zamora-Ávila
- Santiago Saavedra-Alonso
- Edgar Manilla-Muñoz
- Moisés Franco-Molina
- Carmen Mondragón De La Peña
- Cristina Rodríguez-Padilla
View Affiliations

Affiliations: University Autonoma of Nuevo León (UANL), Biological Sciences Faculty, Inmunology and Virology Department, San Nicolás de los Garza, Nuevo León, Mexico , University Autonoma of Nuevo León (UANL), Veterinary Medicine Faculty, Genetics Department, Escobedo, Nuevo León, Mexico , Academic Unit of Biological Sciences, University Autonoma of Zacatecas (UAZ), Guadalupe, Zacatecas, Mexico
Published online on: August 31, 2012 https://doi.org/10.3892/etm.2012.692
Pages: 901-905

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The increased incidence of cancer in recent years is associated with a high rate of mortality. Numerous types of cancer have a low percentage of CD133+ cells, which have similar features to stem cells. The CD133 molecule is involved in apoptosis and cell proliferation. The aim of this study was to determine the biological effect of CD133 suppression and its role in the chemosensitization of cancer cell lines. RT-PCR and immunocytochemical analyses indicated that CD133 was expressed in the cancer cell lines B16F10, MCF7 and INER51. Downregulation of CD133 by transfection with an antisense sequence (As-CD133) resulted in a decrease in cancer cell viability of up to 52, 47 and 22% in B16F10, MCF-7 and INER51 cancer cell lines, respectively. This decreased viability appeared to be due to the induction of apoptosis. In addition, treatment with As-CD133 in combination with cisplatin had a synergic effect in all of the cancer cell lines analyzed, and in particular, significantly decreased the viability of B16F10 cancer cells compared with each treatment separately (3.1% viability for the combined treatment compared with 48% for 0.4 µg As-CD133 and 25% for 5 ng/µl cisplatin; P<0.05). The results indicate that the downregulation of CD133 by antisense is a potential therapeutic target for cancer and has a synergistic effect when administered with minimal doses of the chemotherapeutic drug cisplatin, suggesting that this combination strategy may be applied in cancer treatment.

View Figures

View References

1	Greenwald P and Dunn BK: Landmarks in the history of cancer epidemiology. Cancer Res. 69:2151–2162. 2009. View Article : Google Scholar : PubMed/NCBI
2	Gray-Schopfer V, Wellbrock C and Marais R: Melanoma biology and new targeted therapy. Nature. 445:851–857. 2007. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Murray T, Ward E, et al: Cancer statistics. CA Cancer J Clin. 55:10–30. 2005.
4	Organización Mundial de la Salud [OMS]: 2011.Cáncer. Nota descriptiva No. 297. http://www.who.int/mediacentre/factsheets/fs297/es/index.htmluri. Accessed April 16, 2012.
5	MacKie RM, Hauschild A and Eggermont AMM: Epidemiology of invasive cutaneous melanoma. Ann Oncol. 20(Suppl 6): vi1–7. 2009. View Article : Google Scholar : PubMed/NCBI
6	Bongiorno MR, Doukaki S, Malleo F and Aricò M: Identification of progenitor cancer stem cell in lentigo maligno melanoma. Dermatol Ther. 21(Suppl 1): S1–S5. 2008. View Article : Google Scholar : PubMed/NCBI
7	Rappa G, Fodstad O and Lorico A: The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells. 26:3008–3017. 2008. View Article : Google Scholar : PubMed/NCBI
8	Shmelkov SV, Jun L, St Clair R, et al: Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood. 103:2055–2061. 2004. View Article : Google Scholar : PubMed/NCBI
9	Beier D, Hau P, Proescholdt M, et al: CD133⁺ and CD133⁻ glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67:4010–4015. 2007.PubMed/NCBI
10	Bruno S, Bussolati B, Grange C, Collino F, Graziano ME, Fernando U and Camussi G: CD133⁺ renal progenitor cell contribute to tumor angiogenesis. Am J Pathol. 169:2223–2236. 2006.
11	Sims AH, Howell A, Howell SJ and Clarke RB: Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol. 4:516–525. 2007. View Article : Google Scholar : PubMed/NCBI
12	Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV and Varticovski L: Brca1 breast tumor contain distinct CD44⁺/CD24⁻ and CD133⁺ cell with cancer stem cell characteristic. Breast Cancer Res. 10:R102008. View Article : Google Scholar : PubMed/NCBI
13	Dou J, Pan M, Wen P, et al: Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol. 4:467–472. 2007.PubMed/NCBI
14	Huang EH, Heidt DG, Li CW and Simeone DM: Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. Surgery. 141:415–419. 2007. View Article : Google Scholar : PubMed/NCBI
15	Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F and Duo K: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 62:1212–1218. 2008. View Article : Google Scholar : PubMed/NCBI
16	Dell’Albani P: Stem cell marker in gliomas. Neurochem Res. 33:2407–2415. 2008.
17	Abbott A: Cancer: the root of the problem. Nature. 442:742–743. 2006. View Article : Google Scholar : PubMed/NCBI
18	Maeda S, Shinchi H, Kurahara H, et al: CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 98:1389–1397. 2008. View Article : Google Scholar : PubMed/NCBI
19	Tirino V, Desiderio V, d’Aquino R, et al: Detection and characterization of CD133⁺ cancer stem cells in human solid tumours. PLoS One. 3:e34692008. View Article : Google Scholar : PubMed/NCBI
20	Liu G, Yuan X, Zeng Z, et al: Analysis of gene expression and chemoresistence of CD133⁺ cancer stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
21	Shmelkov SV, Butler JM, Hooper AT, et al: CD133 expression is not restricted to stem cells, and both CD133⁺ and CD133⁻ metastatic colon cancer cells initiate tumors. J Clin Invest. 118:2111–2120. 2008.PubMed/NCBI
22	Al Dhaybi R, Sartelet H, Powell J and Kokta V: Expression of CD133⁺ cancer stem cells in childhood malignant melanoma and its correlation with metastasis. Mod Pathol. 23:376–380. 2010.
23	Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ and Tahan SR: Increased expression of stem cell markers in malignant melanoma. Mod Pathol. 20:102–107. 2007. View Article : Google Scholar : PubMed/NCBI
24	Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ and Molven A: Expression of the stem cell marker CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 8:482008. View Article : Google Scholar : PubMed/NCBI
25	Yang C, Yang Y, Gupta N, et al: Pentaspan membrane glycoprotein, prominin 1, is involved in glucose metabolism and cytoskeleton alteration. Biochemistry (Mosc). 72:854–862. 2007. View Article : Google Scholar : PubMed/NCBI
26	Guo F, Li Y, Liu Y, Wang J and Li G: ARL6IP1 mediates cisplatin-induced apoptosis in CaSki cervical cancer cells. Oncol Rep. 23:1449–1455. 2010.PubMed/NCBI